Quantum Blue® UEGW Posters on fecal pancreatic Elastase and Infliximab and Adalimumab concentration from capillary blood.
At UEG Week 2022 BÜHLMANN presented two new posters on Quantum Blue® assays.
Measuring adalimumab and infliximab trough levels from finger prick blood samples with a rapid point-of-care assay
Serum assays for anti-TNF levels have shown their utility in therapy monitoring for some years already. However, serum preparation from whole blood requires laboratory equipment, is time consuming and can be difficult to integrate into clinical routine. In order to perform the tests in clinician’s offices or infusion sites, we have developed two new point-of-care assays for the quantitative determination of adalimumab and infliximab in capillary or venous (EDTA) whole blood samples.
Development of a New Lateral Flow Assay for the Quantification of fecal Pancreatic Elastase at Point of Care
Fecal pancreatic elastase is an ideal biomarker for the assessment of pancreatic function in patients suffering from pancreatic exocrine insufficiency. BÜHLMANN has successfully launched the high throughput turbidimetric fecal pancreatic elastase assay, BÜHLMANN fPELA® turbo, in 2020. As an attractive alternative, for small laboratories or in a near clinical environment, we have now developed the BÜHLMANN Quantum Blue® fPELA as a quantitative lateral flow assay.